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In This IssueLipoglycopeptide Antibiotic Deacetylases Full Speed Ahead
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Lipoglycopeptide antibiotics are particularly effective against Gram-positive, drug-resistant
bacteria in part because of a fatty acid modification of a sugar residue on the molecule. Prior
to the addition of these fatty acids, dedicated enzymes must remove an acetyl group on the
sugar. Here, Zou et al. describe the structures of enzymes that carry out this task during the
production of the lipoglycopeptide antibiotics teicoplanin and A40926 and show how these
enzymes carry out removal of the acetyl group. The work might aid efforts aimed towards
the production of novel lipoglycopeptide antibiotics. (Figure credits: Zou et al.)
Making Carbs, Using HTS, Seeing HF
PAGE 546
The synthesis of oligosaccharides remains a chemical challenge due to the need to control
stero- and regioselectivity. Glycosynthases are mutant glycosidases that are capable of
catalyzing the formation of a glycosidic linkage between activated glycosyl fluoride donors
and suitable acceptor sugar. Ben-David et al. developed a simple universal high-throughput
screening procedure for monitoring glycosynthase activity. The method relays on detection
of release of hydrofluoric acid, a by-product of all glycosynthase reactions. The authors
applied their method for the directed evolution of a glycosynthase, which led to the isolation
of improved variants. Analysis of these variants suggested a general path for rational optimi-
zation of glycosynthases.
Aurora B Kinase: Resistance is Futile
PAGE 552
The Aurora kinases are serine/threonine kinases important for regulation of mitotic functions.
They have emerged as anticancer drug targets and several inhibitors are in clinical trials.
However, a growing concern is whether tumors will acquire drug resistance. Girdler et al.
now investigate this issue by focusing on cancer cells resistant to a selective Aurora B
inhibitor. The authors develop a screen to identify those cells and demonstrate that all the
resistant clones contained mutations in Aurora B which either block inhibitor binding or hy-
peractivate the kinase. These mutants are also resistant to other classes of Aurora inhibitors.
Therefore, limiting clinical drug resistance will require identification of novel chemical
scaffolds which inhibit the mutants described here. (Figure credits: Girdler et al.)
Orphan Enzymes Find their Substrates
PAGE 563
Characterization of orphan enzymes, for which the catalytic functions and substrates are un-
known, is a significant challenge in the postgenomic era. Furuya et al. describe a general
method for exploring the catalytic potentials of orphan monooxygenases, enzymes that cat-
alyze addition of a single oxygen atom from molecular oxygen into a substrate. The authors employ Fourier transform ion cyclotron
resonance mass spectrometry (FT-ICR/MS) that offers unique advantages due to its remarkable mass resolution and accuracy.
Their analysis functionally assigned two putative cytochrome P450s from Bacillus subtilis. In general, FT-ICR/MS-based approach
streamlines the process of screening for substrates and can be adapted to large-scale screening needed in the genome-wide
characterization.
Taxane Gets a Makeover
PAGE 573
Multidrug resistance of tumor cells is amajor obstacle
in chemotherapy. The predominant cause is the
overexpression of the P-glycoprotein pump. In resis-
tant cells exposed to taxanes (paclitaxel, docetaxel),
two opposing forces control antitumor drug uptake:
binding to target microtubules, keeping the drug
inside the cell, and binding to P-glycoprotein, pump-
ing it out. Matesanz et al. now design novel taxanes
with very high affinity for microtubules, and thus the
ability to overcome resistance, by determining the
effect on the binding affinity of modifications in different positions of the drug molecule and combining the most favorable ones in
a single drug molecule. (Figure adopted from figure provided by Matesanz et al.)Chemistry & Biology 15, June 2008 ª2008 Elsevier Ltd All rights reserved ix
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Morpheeins are homo-oligomeric proteins that reversibly dissociate, change shape, and reassemble differently as an allosteric
control mechanism. Small molecules that specifically bind to one oligomeric assembly are proposed as allosteric drugs. Lawrence
et al. now use in silico and in vitro techniques to discover an allosteric inhibitor that traps porphobilinogen synthase in inactive hex-
americ form. The inhibitor, morphlock-1, binding site is phylogenetically variable and inhibition is species specific, thus identifying this
universally essential protein as a target for antibiotic development. The authors suggest application of this novel inhibitor discovery
strategy to other proteins that function as morpheeins.
SARS-Coronavirus Main Proteinase Structure with Suicide Inhibitor
PAGE 597
The functional importance of the SARS coronavirus main proteinase (Mpro) in the
viral life cycle makes this enzyme an attractive target for the development of anti-
coronaviral therapeutics. Verschueren et al. present crystal structures of the
SARS-CoV Mpro, the active-site cysteine of which has been acylated by benzotria-
zole esters that act as suicide inhibitors. Interestingly, in one of the structures, the
thioester product has been hydrolyzed and benzoic acid is observed to bind to the
hydrophobic S2 pocket. The results further understanding of the important role of
the aminoterminus for catalysis aswell as the design of benzotriazole inhibitors with
improved specificity. (Figure credit: Verschueren et al.)
Adaptive Evolution Applied to Engineering
Synthetic Metabolic Pathways
PAGE 607
Nature has balanced most metabolic pathways such that no one enzyme in the pathway controls the flux through that pathway.
However, unnatural or nonnative, constructed metabolic pathways may have limited production due to unfavorable properties of
one or more enzymes in the pathway. Yoshikuni et al. have used a probable mechanism of adaptive evolution to engineer the in
vivo properties of two enzymes in a constructed metabolic pathway, minimize the bottlenecks in the pathway, and improve the
productivity of the desired final product. This strategy might find broad applicability in the functional construction of biological
pathways in heterologous hosts.
See the Pattern of Salmonella Effector Protein Release
PAGE 619
Here, VanEngelenburg and Palmer develop an experimental approach for imaging direct
secretion of bacterial effector proteins into mammalian cells in real time. The authors
use the FlAsH/tetracysteine in situ chemical labeling technology to detect genomically
tagged effectors. Effectors are under control of endogenous promoters, thus minimally
perturbing the delicate balance of Type-III secretion. The authors detected a difference
in the secretion rate of two Salmonella effector proteins, SopE2 and SptP. The differential
secretion rate suggests there is a temporal hierarchy of effector delivery that is directly
related to effector function. This ‘‘preprogrammed pattern’’ of release has important impli-
cations for understanding bacterial invasion. (Figure credit: VanEngelenburg and Palmer)
Improving Glycosylated Polyenes
PAGE 629
Glycosylated polyenes (GPs) represent a major class of antifungal agents, within which
candicidin appeared as the earliest biosynthesis model of this family. GPs are usually
produced in vivo as a complex of derivative compounds. Detailed understanding of the control mechanisms of their structural
variations and conversions might be of practical significance for structural diversification and obtaining derivatives with improved
pharmacological and/or physicochemical properties. Additionally, generation of strains with predominant production of unique and
superior compounds is also desirable. Zhou et al. now describe results of this approach by using the FR-008/candicidin complex
as a model.x Chemistry & Biology 15, June 2008 ª2008 Elsevier Ltd All rights reserved
